Antibiotic Selection for COPD Exacerbations

Introduction to Antibiotic Selection

The European Respiratory Society recommends co-amoxiclav (amoxicillin-clavulanate) as the first-line antibiotic for hospitalized COPD patients with bacterial exacerbations, with levofloxacin or moxifloxacin as alternatives, unless the patient has risk factors for Pseudomonas aeruginosa 1

Antibiotics are indicated for hospitalized COPD patients with Type I Anthonisen exacerbation, where all three cardinal symptoms are present—increased dyspnea, increased sputum volume, and increased sputum purulence, as recommended by the European Respiratory Society 1, 2, 3
Antibiotics are also indicated for Type II Anthonisen exacerbation with purulence, where two of the three cardinal symptoms are present, including increased sputum purulence, as recommended by the European Respiratory Society 1, 2, 3
The European Respiratory Society recommends antibiotics for severe exacerbations requiring mechanical ventilation, either invasive or non-invasive ventilatory support 1, 2, 3

The European Respiratory Society recommends assessing for Pseudomonas risk factors, including recent hospitalization, frequent antibiotic use, severe airflow obstruction (FEV1 <30%), or recent oral steroids, and using anti-pseudomonal coverage if at least two of these factors are present 1, 2, 4, 3

For patients without Pseudomonas risk factors, the European Respiratory Society recommends co-amoxiclav (amoxicillin-clavulanate) as first-line therapy for moderate-to-severe exacerbations requiring hospitalization 1, 2, 4, 3
For patients with Pseudomonas risk factors, the European Respiratory Society recommends ciprofloxacin or levofloxacin 750 mg daily as the antibiotic of choice 1, 2, 4, 3

The European Respiratory Society recommends treating COPD exacerbations with clinical signs of bacterial infection for 5-7 days, with a switch from IV to oral by day 3 if the patient is clinically stable 1, 2, 4, 3, 5

The European Respiratory Society recommends obtaining sputum cultures or endotracheal aspirates before starting antibiotics in severe exacerbations, or in patients with risk factors for difficult-to-treat organisms (P. aeruginosa) 1, 2, 4, 3

The European Respiratory Society recommends choosing between oral and IV antibiotics based on clinical stability and exacerbation severity, and switching from IV to oral by day 3 if the patient is clinically stable 1, 2, 4, 3

The European Respiratory Society recommends re-evaluating for non-infectious causes, performing careful microbiological reassessment, and changing to an antibiotic with coverage against P. aeruginosa, antibiotic-resistant S. pneumoniae, or non-fermenters in cases of treatment failure 1, 2, 4, 3

The most common bacterial pathogens in COPD exacerbations are Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis, as identified by the European Respiratory Society 6, 7
In patients with risk factors, the European Respiratory Society also considers Pseudomonas aeruginosa, Gram-negative enteric bacilli, and Staphylococcus aureus as potential pathogens 1, 2, 4